Common adverse reactions and coping strategies of lapatinib

Lapatinib, as an innovative oral small molecule drug, has become a highlight in the field of breast cancer treatment with its unique dual inhibitory function, namely targeting epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2) tyrosine kinase. Since being approved by the U.S. Food and Drug Administration (FDA) in 2007, lapatinib has been widely used in the treatment of HER2-overexpressed advanced breast cancer or metastatic breast cancer (MBC), bringing new treatment hope to countless patients.

However, like many other drugs, lapatinib may cause a range of adverse effects during treatment. The diversity and individual differences of these adverse reactions require patients to pay close attention to their physical condition and maintain close communication with the medical team when receiving treatment.

Diarrhea and dermatologic adverse events are commonly reported in patients treated with lapatinib. Diarrhea can range from mild to severe depending on the drug used with lapatinib. Adverse events may reduce quality of life, reduce treatment compliance, and lead to treatment discontinuation. Therefore, aggressive management of diarrhea is critical, especially in patients receiving lapatinib in combination with other drugs that can also cause diarrhea. As the utility of lapatinib expands, critical proactive diarrhea management and dose reduction strategies are being developed to reduce the potential for grade 3 or 4 toxicities. Regarding dermatological adverse events, most were mild to moderate in severity, of limited duration, and generally did not require therapeutic intervention. However, in some patients, management of dermatological adverse events is important.

Overall, lapatinib is an effective breast cancer treatment drug. Although its adverse reactions exist, most patients can tolerate and complete the treatment through reasonable countermeasures and close doctor-patient communication. When receiving treatment, patients should fully understand the potential risks of the drug and conduct scientific self-management and care under the guidance of a doctor.

xa0

Reference materials:https://openurl.ebsco.com/EPDB%3Agcd%3A6%3A1984390/detailv2?sid=ebsco%3Aplink%3Ascholar&id=ebsco%3Agcd%3A48846598&crl=c&link_origin=scholar.google.co.jp